

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Patrick M. Hughes et al.

Serial No.: 10/617,468

Filed: July 10, 2003

For: DELIVERY OF AN ACTIVE DRUG TO
THE POSTERIOR PART OF THE EYE
VIA SUBCONJUNCTIVAL OR
PERIOCLAR DELIVERY OF A
PRODRUG

Examiner: Betton, Timothy E.

Art Unit: 1614

Confirmation No.: 3251

Irvine, California

RESPONSE TO OFFICE ACTION

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

The May 11, 2007 office action (the "Office Action") in this application requested applicant to elect one of Group I (claims 1-17 and 19) and Group II (claims 18 and 20).

Applicant elects Group I, claims 1-17 and 19 with traverse on the basis that since all claims of both Groups I and II are limited to an ester prodrug of an active drug, therefore a single search should suffice to search all the claims.

Additionally, and as also requested by the Office Action, applicant elects the drug retinoids. The claims which appear to be readable on this elected polymer are claims 1-17 and 19.

Additionally, and as also requested by the Office Action, applicant elects the disease proliferative vitreal retinopathy. The claims which appear to be readable on this elected polymer are claims 1-17 and 19.

As further requested by the office action, applicant elects as the route of administration subconjunctival. The claims which appear to be readable on this elected drug species are claims 1-17 and 19.

Respectfully Submitted,

/Stephen Donovan/

Date: June 15, 2007

Stephen Donovan, Reg. No. 33,433

Please direct all correspondence to:

Stephen Donovan
Allergan, Inc. T2 7H
Tower Two, Seventh Floor
2525 Dupont Drive
Irvine, California 92612

Telephone: 714.246.4026

Fax: 714.246.4249